Literature DB >> 11147771

Parovirus B19-associated mono- and oligoarticular arthritis may evolve into a chronic inflammatory arthropathy fulfilling criteria for rheumatoid arthritis or spondylarthropathy.

H D Stahl, R Pfeiffer, G Von Salis-Soglio, F Emmrich.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147771     DOI: 10.1007/s100670070021

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  6 in total

Review 1.  Undifferentiated arthritis and spondylarthropathy as a major problem of diagnosis and classification.

Authors:  H Zeidler
Journal:  Scand J Rheumatol Suppl       Date:  1987

2.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

3.  High incidence of parvovirus B19 DNA in synovial tissue of patients with undifferentiated mono- and oligoarthritis.

Authors:  H D Stahl; B Seidl; B Hubner; S Altrichter; R Pfeiffer; B Pustowoit; U G Liebert; J Hofmann; G von Salis-Soglio; F Emmrich
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

4.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Authors:  M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero
Journal:  Arthritis Rheum       Date:  1991-10

5.  Human parvovirus B19 as a causative agent for rheumatoid arthritis.

Authors:  Y Takahashi; C Murai; S Shibata; Y Munakata; T Ishii; K Ishii; T Saitoh; T Sawai; K Sugamura; T Sasaki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

6.  Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology.

Authors:  S Ehl; J Hombach; P Aichele; T Rülicke; B Odermatt; H Hengartner; R Zinkernagel; H Pircher
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.